Monoclonal gammopathy of undetermined significance epidemiology and demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: – Omer Kamal, M.D.[2]
Overview
The incidence of Monoclonal gammopathy of undetermined significance is approximately 120 per 100,000 in men at age 50, and goes to 530 per 1000 by the age 90. Women however have 60 cases per 1000 at age 50 which goes upto 370 per 1000 at age 90. The prevalence of Monoclonal gammopathy of undetermined significance is different in different populations.
Epidemiology and Demographics
Incidence
- The incidence of Monoclonal gammopathy of undetermined significance is approximately 120 per 100,000 in men at age 50, and goes to 530 per 1000 by the age 90. Women however have 60 cases per 1000 at age 50 which goes upto 370 pwe 1000 at age 90.[1]
- The incidence of Monoclonal gammopathy of undetermined significance was estimated to be higher per 100,000 in men than women worldwide.[2]
Prevalence
- The prevalence of Monoclonal gammopathy of undetermined significance is different in different populations[2]
| Age | Prevalence |
| ≥50 | 3.2 |
| ≥70 | 5.3 |
| ≥85 | 7.5 |
Age
- Monoclonal gammopathy of undetermined significance commonly affects individuals older than 50 years of age. [1]
Race
- Monoclonal gammopathy of undetermined significance usually affects individuals of the african americans and africans[3]. Caucasian individuals are less likely to develop Monoclonal gammopathy of undetermined significance.[3][4]
Gender
- Men are more commonly affected by Monoclonal gammopathy of undetermined significance than women. The men to women ratio is approximately 2 to 1.[1]
Region
- The majority of Monoclonal gammopathy of undetermined significance cases are reported in Africa.[5][3][6][4]
Developed Countries
- Monoclonal gammopathy of undetermined significance is less common in white population areas.
Developing Countries
- Monoclonal gammopathy of undetermined significance is most common in Africa.[3][6]
References
- ↑ 1.0 1.1 1.2 Therneau TM, Kyle RA, Melton LJ, Larson DR, Benson JT, Colby CL, Dispenzieri A, Kumar S, Katzmann JA, Cerhan JR, Rajkumar SV (November 2012). “Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition”. Mayo Clin. Proc. 87 (11): 1071–9. doi:10.1016/j.mayocp.2012.06.014. PMC 3541934. PMID 22883742.
- ↑ 2.0 2.1 Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ (March 2006). “Prevalence of monoclonal gammopathy of undetermined significance”. N. Engl. J. Med. 354 (13): 1362–9. doi:10.1056/NEJMoa054494. PMID 16571879.
- ↑ 3.0 3.1 3.2 3.3 Singh J, Dudley AW, Kulig KA (December 1990). “Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting”. J. Lab. Clin. Med. 116 (6): 785–9. PMID 2246554.
- ↑ 4.0 4.1 Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, Linet MS (February 2006). “Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States”. Blood. 107 (3): 904–6. doi:10.1182/blood-2005-08-3449. PMC 1895893. PMID 16210333.
- ↑ Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, Biritwum RB, Tettey Y, Adjei AA, Larson DR, Dispenzieri A, Melton LJ, Goldin LR, McMaster ML, Caporaso NE, Rajkumar SV (December 2007). “Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana”. Mayo Clin. Proc. 82 (12): 1468–73. doi:10.1016/S0025-6196(11)61089-6. PMID 18053453.
- ↑ 6.0 6.1 Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS (May 1998). “Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly”. Am. J. Med. 104 (5): 439–44. PMID 9626026.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH